Esketamine Market Growth Is Reshaping Competitive Advantage Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Esketamine Market Expansion From $1.66 Billion In 2026 To $2.49 Billion In 2030
The esketamine market has undergone rapid expansion over the last several years. Its value is projected to increase from $1.51 billion in 2025 to $1.67 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.8%. The historical growth is largely explained by factors such as the significant unmet demands in treating major depressive disorder, the well-documented shortcomings of conventional antidepressant therapies, the regulatory endorsement of intranasal esketamine, a growing societal focus on mental health issues, and the proliferation of specialized psychiatric care facilities.
The esketamine market is projected to experience swift expansion over the coming years. By 2030, its value is anticipated to reach $2.5 billion, driven by a compound annual growth rate (CAGR) of 10.6%. This forecasted growth is fueled by factors such as the rising incidence of treatment-resistant depression, a growing need for therapies that work quickly, the expansion of supervised outpatient treatment programs, enhanced mental health infrastructure, and sustained investment in clinical research. Key developments shaping the market during this period include a broader uptake of esketamine for treatment-resistant depression, wider use of nasal spray delivery methods, increasing application in acute psychiatric care settings, stricter monitoring and controlled distribution practices, and ongoing research into rapid-acting antidepressant options.
Download A Free Sample Report For Comprehensive Market Insights:
Esketamine Market Opportunity Drivers: What Is Creating New Revenue Potential?
The growing number of cases of treatment-resistant depression (TRD) is anticipated to accelerate the expansion of the esketamine market in the foreseeable future. This condition is defined as depression that fails to respond after at least two separate trials of antidepressant medications, each taken at an adequate dosage and for a sufficient period. The rise in treatment-resistant depression stems from the limited effectiveness of conventional antidepressants, resulting in prolonged and recurring depressive episodes. Esketamine addresses TRD through its rapid-acting mechanism, which specifically targets NMDA receptors, providing relief for individuals who do not benefit from standard antidepressant therapies. A notable illustration comes from September 2023, when the National Institute of Mental Health (NIMH), a federal entity based in the United States, reported that approximately 30% of Americans diagnosed with major depressive disorder in 2023 exhibit resistance to conventional treatments. Consequently, the increasing frequency of treatment-resistant depression is fueling the upward trajectory of the esketamine market.
Esketamine Market Segment Performance And Strategic Opportunities
The esketamine market covered in this report is segmented –
1) By Formulation Type: Nasal Spray, Injectable Form
2) By Indication: Treatment-Resistant Depression (TRD), Major Depressive Disorder with Suicidal Ideation or Behavior
3) By Patient Type: Adult Patients
4) By Treatment Setting: Hospital-Based Administration, Certified Specialty Clinics
5) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Nasal Spray: Single-Agent Esketamine Nasal Spray, Esketamine + Oral Antidepressant Combination Therapy
2) By Injectable Form: Intravenous (IV) Esketamine, Intramuscular (IM) Esketamine
Esketamine Market Innovation Trends Driving Future Development
Key players in the esketamine market are prioritizing the creation of cutting-edge therapeutic approaches, particularly monotherapy, to achieve superior relief from depressive symptoms compared to a placebo. Monotherapy involves managing a medical condition with a single drug or treatment, avoiding the use of multiple combined therapies. For example, Johnson & Johnson, a pharmaceutical firm based in the U.S., announced in January 2025 that the FDA had approved SPRAVATO (esketamine) as the first standalone monotherapy for adults facing treatment-resistant depression (TRD). Clinical trial results supported this approval, showing that SPRAVATO could rapidly reduce depressive symptoms, with notable improvements appearing within 24 hours. This innovation offers a vital alternative for roughly 30% of patients who fail to benefit from conventional antidepressants, removing the requirement for additional oral medications. Although SPRAVATO presents a favorable safety profile, its administration is governed by a Risk Evaluation and Mitigation Strategy (REMS) to manage possible adverse effects. This achievement represents a substantial step forward in TRD management, providing renewed optimism for enhanced patient outcomes.
Esketamine Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the esketamine market are Johnson & Johnson, Janssen Pharmaceuticals, Sage Therapeutics Inc., VistaGen Therapeutics Inc., Cerecor Inc., Celon Pharma S.A., Hikma Pharmaceuticals plc, Seqens Group, Arevipharma GmbH, Nortec Química S.A., Supriya Lifescience Ltd., Maithri Drugs Pvt. Ltd., SynZeal Research Pvt. Ltd., XWPharma Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Aurobindo Pharma Ltd., H. Lundbeck A/S, Otsuka Pharmaceutical Co. Ltd.
Access The Complete Esketamine Market Report:
Esketamine Market Geographic Distribution And Regional Opportunities
North America was the largest region in the esketamine market in 2025. The regions covered in the esketamine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
